Supplementary Material for: A Comparison of the Safety and Efficacy of HX575 (Epoetin Alfa Proposed Biosimilar) with Epoetin Alfa in Patients with End-Stage Renal Disease
Matthew R. Weir(University of Maryland, Baltimore), Radmila Kančeva, Jogender Kumar(Post Graduate Institute of Medical Education and Research), Gregor Schaffar, Pablo E. Pérgola(Renal Associates P. A.), R. L. Agarwal, Jeffrey C. Fink(Children's Hospital of Philadelphia), Jim P. McKay, A. Rudy, A.K. Singh, Susanne Schmitt, Nelson Kopyt
Cited by 0
Related Papers
Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors
|New England Journal of Medicine|2014|658
The Chronic Renal Insufficiency Cohort (CRIC) Study
|Journal of the American Society of Nephrology|2003|650
MYH9 is associated with nondiabetic end-stage renal disease in African Americans
|Nature Genetics|2008|648